PPARβ/δ有助于抗糖尿病作用和由甲胺引起的GDF15增加
Javier Jurado-Aguilar1,2,3,4, Emma Barroso1,2,3,4, Patricia Rada3,5
1Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028, Barcelona, Spain.
Acta pharmacologica Sinica
|January 16, 2026
概括
甲福明改善葡萄糖耐受性,并通过氧酶增殖器激活受体β/delta (PPARβ/δ) 增加生长分化因子15 (GDF15). 这一途径对甲素至关重要.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 分子生物学分子生物学
背景情况:
- 甲胺是2型糖尿病的主要治疗方法.
- 甲胺增加了循环生长分化因子15 (GDF15) 的水平,主要是通过脏的转录调节.
- 过氧体增殖器激活受体 (PPAR) β/δ激动剂与甲胺具有共同作用,包括GDF15升高.
研究的目的:
- 调查甲福明的抗糖尿病作用和GDF15上调是否取决于PPARβ/δ核受体.
- 阐明PPARβ/δ在甲福林的作用机制中的作用.
主要方法:
- 使用高脂肪饮食 (HFD) 的雄性Ppard淘汰 (Ppard-/-) 和野生型 (WT) 老鼠.
- 给小鼠和培养的 podocytes 进行了甲胺和 PPARβ/δ调节剂 (抗激素 GW501516,抗激素 GSK0660).
- 分析了葡萄糖不耐受性,肝/循环GDF15,/肝蛋白表达 (AMPK,β-arrestin 1,PCSK6).
主要成果:
- 在WT小鼠中,甲胺改善了葡萄糖不耐受性和增加了GDF15,但在Ppard-/-小鼠中没有.
- 在WT小鼠中,甲福明增加了基化AMPK,GDF15,β-arrestin 1和PCSK6;在Ppard-/-小鼠中,这些效应被消除了.
- PPARβ/δ激活模仿了甲胺的作用,而对抗性则阻止了它们在细胞中的作用.
结论:
- 甲福明的降血糖和提高GDF15的作用取决于PPARβ/δ.
- 该研究确定了一个调节轴,其中甲胺利用PPARβ/δ来控制葡萄糖耐受性,AMPK活性和GDF15成熟.
- PPARβ/δ是甲福尔治疗2型糖尿病的关键调解剂.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
587
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
587
Dipeptidyl Peptidase 4 Inhibitors
596
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
596
Glucagon-like Receptor Agonists
850
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
850
Hormones Regulating Blood Glucose
6.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.5K
Cell Specific Gene Expression
16.3K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
16.3K
Oral Hypoglycemic Agents: Glinides
600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600


